(VRDN) Viridian Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.947m USD | Total Return: 26.1% in 12m
Avg Turnover: 37.3M
Qual. Beats: 0
Rev. Trend: 67.0%
Qual. Beats: 0
Warnings
Share dilution 25.7% YoY
Interest Coverage Ratio -32.7 is critical
Altman Z'' -13.15 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Viridian Therapeutics, Inc. (VRDN) is a clinical-stage biotechnology company focused on developing therapies for rare and serious diseases, primarily targeting thyroid eye disease (TED) and Graves disease. The companys pipeline centers on insulin-like growth factor-1 receptor (IGF-1R) inhibitors, including intravenous Veligrotrug and subcutaneous Elegrobart. Additionally, Viridian is advancing neonatal Fc receptor (FcRn) inhibitors, such as VRDN-006 and VRDN-008, designed to modulate immune responses by suppressing IgG antibodies.
The biotechnology sector often utilizes monoclonal antibodies to target specific proteins involved in autoimmune pathways, a strategy that can offer higher specificity than traditional systemic treatments. Viridian operates under a research and development business model, where value is driven by clinical trial progression and the attainment of regulatory milestones prior to commercialization. Investors should review ValueRay for further quantitative analysis of the companys financial position.
- Clinical trial data for Veligrotug determines competitive positioning against established TED treatments
- Regulatory approval timelines for subcutaneous Elegrobart impact long-term market share potential
- Expansion into Graves’ disease market diversifies revenue beyond thyroid eye disease
- Research and development expenses for FcRn inhibitor portfolio influence cash runway
- Market competition from Amgen’s Tepezza dictates pricing power and adoption rates
| Net Income: -360.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA 2.78 > 1.0 |
| NWC/Revenue: 1.03k% < 20% (prev 206k%; Δ -205k% < -1%) |
| CFO/TA -0.38 > 3% & CFO -303.4m > Net Income -360.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.2m) vs 12m ago 25.65% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 9.78% > 50% (prev 0.05%; Δ 9.74% > 0%) |
| Interest Coverage Ratio: -32.69 > 6 (EBITDA TTM -364.3m / Interest Expense TTM 11.1m) |
| A: 0.93 (Total Current Assets 784.7m - Total Current Liabilities 51.8m) / Total Assets 789.0m |
| B: -1.83 (Retained Earnings -1.44b / Total Assets 789.0m) |
| C: -0.50 (EBIT TTM -364.3m / Avg Total Assets 725.0m) |
| D: -9.43 (Book Value of Equity -1.44b / Total Liabilities 153.0m) |
| Altman-Z'' = -13.15 = D |
As of May 24, 2026, the stock is trading at USD 17.69 with a total of 1,455,470 shares traded.
Over the past week, the price has changed by +2.50%,
over one month by +20.31%,
over three months by -38.58% and
over the past year by +26.12%.
Viridian Therapeutics has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy VRDN.
- StrongBuy: 9
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 33.9 | 91.9% |
P/S = 27.452
P/B = 3.8588
Revenue TTM = 70.9m USD
EBIT TTM = -364.3m USD
EBITDA TTM = -364.3m USD
Long Term Debt = 50.4m USD (from longTermDebt, last quarter)
Short Term Debt = 738k USD (from shortTermDebt, last quarter)
Debt = 51.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 738k
Net Debt = -635.3m USD (calculated: Debt 51.9m - CCE 687.2m)
Enterprise Value = 1.31b USD (1.95b + Debt 51.9m - CCE 687.2m)
Interest Coverage Ratio = -32.69 (Ebit TTM -364.3m / Interest Expense TTM 11.1m)
EV/FCF = -4.18x (Enterprise Value 1.31b / FCF TTM -314.1m)
FCF Yield = -23.95% (FCF TTM -314.1m / Enterprise Value 1.31b)
FCF Margin = -442.9% (FCF TTM -314.1m / Revenue TTM 70.9m)
Net Margin = -508.5% (Net Income TTM -360.6m / Revenue TTM 70.9m)
Gross Margin = unknown ((Revenue TTM 70.9m - Cost of Revenue TTM 1.16m) / Revenue TTM)
Tobins Q-Ratio = 1.66 (Enterprise Value 1.31b / Total Assets 789.0m)
Interest Expense / Debt = 21.47% (Interest Expense 11.1m / Debt 51.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -287.8m (EBIT -364.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.05 (Total Current Assets 784.7m / Total Current Liabilities 65.1m)
Debt / Equity = 0.08 (Debt 51.9m / totalStockholderEquity, last quarter 636.0m)
Debt / EBITDA = 1.74 (negative EBITDA) (Net Debt -635.3m / EBITDA -364.3m)
Debt / FCF = 2.02 (negative FCF - burning cash) (Net Debt -635.3m / FCF TTM -314.1m)
Total Stockholder Equity = 594.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -49.74% (Net Income -360.6m / Total Assets 789.0m)
RoE = -17.70% (Net Income TTM -360.6m / Total Stockholder Equity 2.04b)
RoCE = -17.45% (EBIT -364.3m / Capital Employed (Equity 2.04b + L.T.Debt 50.4m))
RoIC = -39.00% (negative operating profit) (NOPAT -287.8m / Invested Capital 738.0m)
WACC = 8.42% (E(1.95b)/V(2.00b) * Re(8.19%) + D(51.9m)/V(2.00b) * Rd(21.47%) * (1-Tc(0.21)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 37.80%
[DCF] Fair Price = unknown (Cash Flow -314.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.66 | # QB: 0
Revenue Correlation: 66.96 | Revenue CAGR: 506.4% | SUE: 0.01 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.04 | Chg30d=-4.02% | Revisions=+11% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.98 | Chg30d=-4.13% | Revisions=+11% | Analysts=10
EPS current Year (2026-12-31): EPS=-3.81 | Chg30d=+2.09% | Revisions=+20% | GrowthEPS=-14.9% | GrowthRev=-52.5%
EPS next Year (2027-12-31): EPS=-2.51 | Chg30d=-7.24% | Revisions=+9% | GrowthEPS=+34.2% | GrowthRev=+627.1%
[Analyst] Revisions Ratio: +20%